Generic Medicine Info
Indications and Dosage
Ocular infections
Adult: As 10%, 15% or 30% sulfacetamide Na soln: Instill 1-2 drops into the conjunctival sac of the affected eyes(s) 2-3 hourly. As 10% sulfacetamide Na ointment: Apply approx half inch onto affected eye(s)  3-4 hourly and at bedtime. Taper dose by increasing dosage time interval as condition responds. Usual duration of treatment: 7-10 days.
Hypersensitivity; infants <2 mth.
Special Precautions
Elderly. History of allergy or asthma; G6PD deficiency; renal and hepatic impairment. Prolonged therapy requires CBC and urinalysis with microscopic examination. Maintain adequate fluid intake. Pregnancy, lactation.
Adverse Reactions
Hypersensitivity skin reaction. Ophthalmic: Burning, stinging, conjunctivitis, corneal ulcers, irritation, conjunctival hyperaemia. Systemic absorption from inflamed conjunctiva.
Potentially Fatal: Stevens-Johnson syndrome.
Ophth/Topical: C
Drug Interactions
Action antagonised by PABA and procaine group of local anaesthetics. PABA present in purulent eye exudates can competitively inhibit the action of sulphacetamide.
Lab Interference
May interfere with diagnostic tests e.g. urinary glucose, urobilinogen, urea and creatinine.
Mechanism of Action: Sulfacetamide has bacteriostatic effect on a wide range of gram-positive and gram-negative organisms. It interferes with nucleic acid synthesis thus blocking conversion of PABA to the coenzyme dihydrofolic acid.
Absorption: Penetrates into ocular tissues and fluids (ophthalmic).
Excretion: Urine (as unchanged drug); 7-13 hr (elimination half-life).
Store below 25°C.
MIMS Class
Eye Anti-Infectives & Antiseptics
Disclaimer: This information is independently developed by MIMS based on Sulfacetamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in